FactSet vs Veeva

10-K Financial Filing Analysis for FactSet (2026-10-20)

FactSet Research Systems Inc. reported its fiscal year 2026 financial results (period ended August 31, 2026), generating total revenues of $2,476.3 million, up 6.7% year-over-year from $2,321.7 million in fiscal 2025. Organic Annual Subscription Value (ASV) expanded by 7.0% to $2,568.2 million, driven by demand for data solutions and workstations. Operating income contracted 6.5% to $700.0 million, resulting in an operating margin compression of 390 basis points to 28.3%, weighed down by $46.2 million in restructuring costs, higher variable compensation, and executive onboarding expenses. Net income declined 10.6% to $533.5 million, with diluted EPS decreasing 6.3% to $14.57, cushioned by share buybacks reducing share count. Operating cash flows improved to $822.2 million, yielding free cash flow of $707.5 million, supporting $808.1 million in total capital returns through share repurchases and dividends.

• Revenues rose 6.7% to $2,476.3 million, while Organic ASV climbed 7.0% to $2,568.2 million as client count grew 2.9% to 9,258 and user count expanded 9.8% to 260,671.
• Operating margin declined from 32.2% to 28.3%, primarily due to $46.2 million in severance/restructuring expenses, executive onboarding compensation of $19.5 million, and higher merit/cloud hosting costs.
• Capital return totaled $808.1 million in fiscal 2026, comprising $644.0 million in share repurchases (2,608,284 shares) and $164.2 million in cash dividends, with the quarterly dividend raised to $1.16 per share.

8-K Financial Filing Analysis for FactSet (2026-08-31)

On August 28, 2026, FactSet Research Systems Inc. entered into Amendment No. 1 to its credit agreement with PNC Bank, National Association, as administrative agent, and participating lenders. The amendment increases the aggregate commitments under its senior unsecured revolving credit facility by $500 million, bringing the total revolving capacity to $1.5 billion, while extending its maturity date to August 28, 2031. Additionally, the amendment extends the final maturity of its $375 million senior unsecured term loan facility to August 28, 2029, eliminates scheduled term loan amortization, and removes the 0.10% credit spread adjustment on Term SOFR and Daily Simple SONIA borrowings.

• Expanded the senior unsecured revolving credit facility commitment by $500M to $1.5B and extended maturity to August 28, 2031.
• Extended the $375M senior unsecured term loan maturity to August 28, 2029, and eliminated scheduled amortization payments.
• Removed the 0.10% credit spread adjustment for Term SOFR and Daily Simple SONIA borrowings.

8-K Financial Filing Analysis for FactSet (2026-09-30)

FactSet Research Systems Inc. filed a Form 8-K reporting two primary events: the issuance of its fourth-quarter and full-year earnings press release for the period ended August 31, 2026, and the adoption of amendments to its Amended and Restated By-laws, effective September 24, 2026. The by-law amendments enhance the Board's authority to delegate powers to Board committees in accordance with Delaware General Corporation Law, update advance notice requirements and procedural disclosures for shareholder nominations and business proposals, and implement clarifying revisions regarding officer appointments and standardized definitions.

• On September 30, 2026, FactSet furnished its financial results for the three and twelve months ended August 31, 2026 (Item 2.02, Exhibit 99.1).
• On September 24, 2026, the Board approved Amended and Restated By-laws, effective immediately, enabling broader Board committee delegation under Delaware law and refining advance notice procedures for shareholder meetings (Item 5.03, Exhibit 3.1).
• The filing was executed by Executive Vice President and Chief Financial Officer Joshua Warren on September 30, 2026.

IQVIA Expands Veeva Partnership with Clinical Operations Applications

IQVIA and Veeva Systems announced an expansion of their partnership, with IQVIA selecting Veeva CTMS, eTMF, Study Startup, and Site Connect as enterprise standard applications for its clinical development studies. This extends the previously announced EDC partnership. The collaboration aims to increase trial speed and efficiency, strengthen site centricity, and improve decision-making for clinical research customers. All Veeva clinical solutions will also be available through IQVIA for sponsors seeking a full Veeva technology stack. Executives from both companies emphasized the benefits of integrated technologies and customer flexibility in choosing EDC, RTSM, and eCOA solutions. The announcement was made on October 13, 2026, ahead of the Veeva R&D and Quality Summit scheduled for October 20-21 in Boston.

• IQVIA selected Veeva CTMS, eTMF, Study Startup, and Site Connect as enterprise standard applications.
• Partnership expansion extends the previously announced EDC partnership.
• All Veeva clinical solutions will be available through IQVIA for sponsors.

Servier Adopts Veeva OpenData Globally for AI

Servier, a French pharmaceutical company, is standardizing its customer reference data across more than 80 countries with Veeva OpenData, part of Veeva Data Cloud. This initiative builds on Servier's use of Veeva Link Key People and aims to create an AI-ready data foundation by harmonizing fragmented data silos. The centralized data will help commercial and medical teams gain faster insights and improve efficiency. Liam Hanrahan, Director of Global Operations Excellence at Servier, highlighted that the centralized data will improve processes and enable a semantic layer for better engagement with key healthcare professionals. Veeva's president, Kilian Weiss, emphasized that 89% of AI initiatives fail due to data challenges, and Servier's data-first approach demonstrates industry leadership. The adoption replaces fragmented silos and ensures consistency for scaling advanced analytics and AI.

• Servier standardizes customer reference data with Veeva OpenData across more than 80 countries.
• The initiative builds on Servier's use of Veeva Link Key People.
• Veeva OpenData is part of Veeva Data Cloud, which also includes Veeva Link and Veeva Compass.

New Veeva Study Builder Agent to Configure Clinical Studies in as Little as One Day

Veeva announces a new Study Builder Agent that can configure clinical studies in as little as one day, along with other updates including another Top 20 biopharma choosing Vault CRM and the introduction of Falcon Router for agentic triage.